**2018 Post-SITC Conference**

**Date：24th March, Saturday .**

* **Research track [Ballroom II] 10:00-12:25**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topic | Speaker | Moderator |
|  | **Adaptive T cell therapy & Oncolytic virus** | | |
| 1000-1005 | Opening | John Wen-Cheng Chang  張文震 | |
| 1005-1045 | Immunotherapy: Focusing on adoptive T cell therapy | Yen-Ling Chiu 邱彥霖 | John Yu  游正博 |
| 1045-1125 | Oncolytic virus: SITC updates & future perspectives | John Tsu-An Hsu 徐祖安 | Shin-Ru Shih 施信如 |
| 1125-1230 | Lunch | | |
|  | **Moving to Main tract** | | |

* **Nurse tract [Ballroom I] 10:00-16:00**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topic | Speaker | Moderator |
|  | **Real world networking on immune related adverse events** | | |
| 1000-1005 | Opening | Sui-Whi Jane 簡淑慧 John Wen-Cheng Chang 張文震 | |
| 1005-1045 | Multidisciplinary work in cancer immunotherapy | Yu-Fen Lin  林玉芬 | Shiow-Ching Shun 孫秀卿 |
| 1045-1125 | Nursing care for immunotherapy in cancer patients | Wen-Tzu Chiu  徐文姿 |
| 1125-1230 | Lunch | | |
|  | **Moving to Main tract** | | |
| 1410-1430 | Coffee break | | |
|  | **Real work practice on immune related adverse events** | | |
| 1430-1600 | Case discussion in groups\*  Only invited people allowed | Laura S. Wood | Cheng-Hsu Wang 王正旭 |

\*On-site simultaneous interpretation

* **Main track [Ballroom I] 12:30-16:00**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Time | Topic | | Speaker | Moderator |
|  | Real world networking on immune related adverse events | | | |
| 1230-1340 | **Keynote speech**  Optimal side effect management from target therapy to the immunotherapy era | Laura S. Wood | | Sui-Whi Jane  孫秀卿 |
| 1340-1410 | Guideline of irAEs management | John Wen-Cheng Chang 張文震 | | Yi-Fang Chang  張義芳 |
| 1410-1430 | Coffee break | | | |
|  | [Post-SITC] Science Behind the Therapy: Mechanisms of Toxicity, Ballroom I | | | |
| 1430-1450 | Colitis | Chueh-Chuan Yen  顏厥全 | | Yee Chao 趙毅 |
| 1450-1510 | Cardiovascular autoimmunity | Meng-Ting Peng  彭夢婷 | |
| 1510-1530 | Autoimmune endocrinopathies | Maio-Jen Liu  劉妙真 | | Alex Yuang-Chi Chang 張元吉 |
| 1530-1550 | Severe Neurotoxicity, esp. in the Phase 2 Trial of JCAR015 in Adult B-ALL (ROCKET Study) | Yu-Hsiang Chang  張裕享 | |
| 1550- | Closing | | | |

\*On-site simultaneous interpretation

**Date：25th March, Sunday**

* **Main track [Ballroom I]** **09:00-15:00**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Time | Topic | | Speaker | Moderator |
|  | **Mechanisms of Acquired Resistance to Immunotherapies** | | | |
| 0900-0925 | Acquired Resistance to Checkpoint Inhibitors in Lung Cancer | | Chao-Hua Chiu  邱昭華 | Alice Lin-Tsing Yu 陳鈴津 |
| 0925-0950 | Acquired Resistance to PD-1 Blockade in Melanoma | | Hsiang-Fong Kao  高祥豐 |
| 0950-1010 | Immune mechanism of immune related adverse events | Chung-Bing Chen  陳俊賓 | | Wen-Hung Chung  鐘文宏 |
| 1010-1030 | Coffee break | | | |
|  | **Cancer immunotherapy** | | | |
| 1030-1130 | **Keynote speech**  Cancer Immunotherapy: Research, Therapy and Regulations | | Lisa H. Butterfield | Ann-Lii Cheng  鄭安理 |
| 1130-1150 | How to provide high-quality care for cancer patient? | | Po-Chang Lee  李伯璋 |
| 1150-1230 | Panel Discussion | | ALL | |
| 1230-1330 | Lunch & Break | | | |
| 1230-1300 | The Second General Assembly of Taiwan Society of Immunotherapy for Cancer,  Ballroom II | | | |
|  | **Late break SITC abstract & High Impact Clinical Trial Results** | | | |
| 1330-1350 | Update IO therapies in NSCLC | | Feng-Che Kuan  官鋒澤 | Meng-Chih Lin  林孟志 |
| 1350-1410 | Update IO therapies in GU cancers | | Ying-Hsu Chang  張英勛 | Chang-Fang Chiu 邱昌芳 |
| 1410-1450 | Update IO therapies in melanoma and other cancers | | Chen-Yuan Lin  林振源 | JohnWen-Cheng Chang 張文震 |
| 1450- | Closing | | John Wen-Cheng Chang 張文震 | |

**Date：25th March, Sunday** .

* **Pharmacist track [Ballroom II] 09:00-10:30**

|  |  |  |  |
| --- | --- | --- | --- |
| Time | Topic | Speaker | Moderator |
|  | **Pharmacists in the era of immune checkpoint inhibitors** | | |
| 0900-0905 | Opening | Fe-Lin Lin Wu 林慧玲 | |
| 0905-0930 | The role of pharmacists in the era of immune checkpoint inhibitors | Chi-Yuan Cheng  鄭吉元 | Shin-Tarng Deng 鄧新棠 |
| 0930-1010 | Immune checkpoint inhibitors: What pharmacists need to know | Chi-Yuan Cheng  鄭吉元 |
| 1010-1030 | Coffee break |  |  |
|  | **Moving to Main tract** | | |